Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN052 in advanced solid tumors
NCT05309512Phase 1Terminated
- Sponsor
- Alphamab Oncology
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN052 in solid tumor (advanced stage), sponsored by Alphamab Oncology. Primary endpoints: Maximum Tolerated Dose at 1 year, Objective Response Rate at 1 year and 1 more. Started May 2022; status: terminated.
02
Drugs
KN052
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05309512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309512.